Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LESS-AD Trial
NCT07234695Phase 3Recruiting
- Sponsor
- Hospital de la Santa Creu i Sant Pau Research Institute
- Start
- Dec 2025
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in epilepsy and Alzheimer's disease (AD) comparing Levetiracetam 500 mg/12h with Placebo (2 arms). Primary endpoint: Efficacy of Levetiracetam as a preventive treatment for epileptic seizures at 96 weeks. Started Dec 2025; status: recruiting.
02
Drugs
levetiracetam
03
Conditions
epilepsyAlzheimer's disease (AD)
Beyond the preview
Go deeper on NCT07234695.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07234695.